New Pancreatic Cancer Drug Doubles Survival Rates

A breakthrough treatment called daraxonrasib has doubled survival rates for metastatic pancreatic cancer patients, reducing their risk of death by 60 percent.

This major medical win came from peer-reviewed scientific research, proving that sustained investment in science saves lives.